VRTX
Vertex Pharmaceuticals Incorporated
NASDAQ · Healthcare · Biotechnology · US
$546.12
−2.12%Year over year
Reported trailing growth
- Revenue
- +10.6%
- EBITDA
- +18.6%
- EBIT
- +24.2%
- EPS
- +22.5%
- Free cash flow
- +8.5%
- Operating cash flow
- +11.6%
Forward estimates
Based on analyst estimates
- Revenue
- +10.0%
- EBITDA
- +42.5%
- EPS
- +12.5%
Three-year CAGR
- Revenue
- +10.6%
- EBITDA
- +3.1%
- EBIT
- +3.4%
- Net income
- +6.0%
- EPS
- +6.0%
- Free cash flow
- -6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026